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Metabolism of drugs by the kidney
M. W. ANDERS
Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota
The kidneys have many clearly defined physio-
logic functions. Although their role as an excretory
organ for drugs and chemicals and their polar me-
tabolites is well described, their involvement in the
biotransformation of xenobiotics is relatively poor-
ly understood. It is accurate to state that our pres-
ent understanding of the metabolic processes of
drugs is based largely on studies carried out in the
liver. Only recently have detailed investigations in-
to drug metabolism in the kidney been carried out.
These studies have shown that the kidney is meta-
bolically very active in effecting the biotransforma-
tion of a variety of chemicals and drugs and, in
some cases, surpasses the liver.
It is important to understand the role of the kid-
ney in drug and chemical biotransformation for a
variety of reasons. Because the kidney receives a
substantial portion of the cardiac output, it is rea-
sonable to expect that it may make a significant con-
tribution to the total metabolic alteration of drugs in
the body. Furthermore, it is now known that the
toxic effects of many drugs and chemicals are attrib-
utable to their metabolic conversion to reactive
electrophilic intermediates, which, on reaction with
cellular nucleophiles, lead to a variety of dele-
terious effects. Perhaps most important is the ap-
preciation that this interaction between reactive in-
termediates and critical cellular macromolecules is
intimately involved in mutagenic and carcinogenic
changes. In addition, necrotic changes may also be
associated with cellular alkylation. Thus, a com-
plete perspective on the role of the kidney in phar-
macologic and toxicologic processes is dependent
on a thorough understanding of the drug and chem-
ical metabolic capabilities of this organ.
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The biotransformation of organic compounds can
be conveniently divided into oxidative, reductive,
hydrolytic, and synthetic or conjugation reactions.
The first three reactions are based on the type of
chemical change produced. Synthetic or conjuga-
tion reactions usually involve the enzyme-catalyzed
combination of a chemical or a metabolite and a car-
bohydrate or an amino acid, and they yield highly
polar, readily excretable metabolites. Furthermore,
multiple metabolic alterations are very common.
Williams, in his classic book, Detoxication Mecha-
nisms, suggests that the metabolism of many xeno-
biotics occurs in two steps [1]. The first, termed
"phase I reactions," includes oxidative, reductive,
and hydrolytic reactions; the second, termed
"phase II reactions," consists of conjugative reac-
tions and includes, for example, glucuronide, sul-
fate, and hippuric acid formation. It should be noted
that although the metabolites produced in phase I
reactions are frequently less toxic or less active
pharmacologically than the parent compound is,
abundant examples can be cited where the metabo-
lites are more toxic and more active pharmacolog-
ically. By the same token, although the conjugates
produced in phase II reactions are usually very po-
lar and less toxic, notable exceptions exist; for ex-
ample, the sulfate conjugate of N-hydroxyacetyl-
aminofluorene is thought to be the proximate car-
cinogen in the case of this compound [51.
Oxidative reactions
Cytochrome P-450-dependent oxidations. An im-
portant development in drug metabolism has been
the elucidation of the role of cytochrome P-450-de-
pendent mixed-function oxidases in catalyzing oxi-
dative reactions. This enzyme system is localized in
the smooth endoplasmic reticulum or microsomal
fraction of many organs.
It has been known for many years that the en-
zymes catalyzing the oxidation of xenobiotics were
present in microsomal fractions of liver. These en-
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zymes required NADH and molecular oxygen for
activity [3, 4] and catalyzed a variety of oxidative
reactions commonly termed "hydroxylation" reac-
tions. Included are aromatic and aliphatic hydroxy-
lation, N-, 0- and S-dealkylations, sulfoxidation,
N-oxidation, and epoxidation.
It is now known that the microsomal oxidase sys-
tem is comprised of three components: a hemo-
protein, a flavoprotein reductase, and a lipid factor
[5].
The presence of a carbon-monoxide-binding pig-
ment in hepatic microsomal fractions was reported
by Klingenberg [6] and Garfinkel [7]. Its hemo-
protein nature was described by Omura and Sato [8,
9], and it was termed cytochrome P-450" because
the carbon-monoxide-difference spectrum of dithi-
onite-reduced microsomes showed an intense ab-
sorption maximum at 450 mj.t. Although these spec-
tral properties were unusual, a catalytically inactive
degradation product of cytochrome P-450, termed
"cytochrome P-420," showed an absorption maxi-
mum at 420 m and appeared to be a b-type cyto-
chrome. Maines and Anders [10] later showed by
gas chromatography and mass spectrometry that
the porphyrin portion of cytochrome P-450 was, in
fact, protoporphyrin IX.
Definitive evidence for the involvement of cyto-
chrome P-450 in microsomal oxidations was pro-
vided by Cooper et al [11] and Omura et al [12], who
reported that carbon monoxide-inhibited cyto-
chrome P-450 catalyzed drug metabolism in vitro;
furthermore, light reversed this inhibition, and the
photochemical action spectrum of this reversal cor-
responded to the absorption spectrum of the cyto-
chrome P-450-carbon monoxide complex. In addi-
tion, agents that increase or decrease cytochrome
P-450 levels usually produce parallel changes in
rates of microsomal drug metabolism [13, 14]. Fi-
nally, many chemicals known to serve as substrates
for microsomal mixed-function oxidases bind to
cytochrome P-450 to produce characteristic dif-
ference spectra [15]. Although there seems little
doubt that these binding spectra represent an inter-
action between cytochrome P-450 and chemical,
their precise interpretation remains somewhat un-
certain. This evidence has been discussed by Man-
nering [16].
Because only reduced cytochrome P-450 will
bind oxygen, the involvement of a reductase is an
obligatory component of the electron transport sys-
tem for mixed-function oxidases. Furthermore, re-
duced cytochrome P-450 may serve as an electron
donor in some reductive reactions, without binding
oxygen. The reduction of cytochrome P-450 is cata-
lyzed by NADPH-cytochrome P-450 reductase, a
membrane-bound fiavoprotein. This reductase is
identical to NADPH-cytochrome c reductase and
has recently been purified to homogeneity [17, 18].
Evidence suggesting that reduction of cytochrome
P-450 may be the rate-limiting step in cytochrome-
P-450-catalyzed oxidations has been summarized
by Björkhem [19]. Gander and Mannering [20] have
shown, however, that the concept of a single rate-
limiting step may not be applicable to microsomal
mixed-function oxidations.
The involvement of a second hemoprotein, cyto-
chrome b5, in microsomal oxidations was described
by Hildebrandt and Estabrook [21]. This pigment
can serve as an electron donor to cytochrome P-450
and, thus, plays an important role in oxidative drug
metabolism. Gander and Mannering [20] have dis-
cussed in detail the role of cytochrome b5 in drug
metabolism.
Finally, the cytochrome P-450 system was shown
to require a heat-stable lipid factor [5]. This was
subsequently identified as phosphatidylcholine [22].
It serves to facilitate electron transfer in micro-
somal systems, but its detailed role is not well un-
derstood.
A scheme depicting the oxidation of chemicals by
cytochrome P-450-dependent mixed-function oxi-
dases is shown in Fig. 1. The substrate first binds to
oxidized cytochrome P-450(cyt-Fe3), which is re-
duced by electrons from NADPH, via NADPH-
cytochrome P-450 reductase, to yield the substrate-
reduced cytochrome P-450 complex (S-cyt-Fe2).
This reduced intermediate can bind oxygen (or car-
bon monoxide) to give a substrate-oxygen-reduced
cytochrome P-450 complex (S-cyt-Fe2-O2). Dona-
tion of a second electron from NADPH, via
NADPH-cytochrome P-450 reductase, or, in certain
cases, NADH, via NADH-cytochrome b5 reduc-
tase, serves to reduce the oxygen bound to the he-
moprotein (S-cyt-Fe2-O2). Loss of water yields
the active oxygen" species, thought to be formally
similar to compound I of catalase or an oxenoid spe-
cies [23] (S-cyt-Fe3-O), which serves to hydroxy-
late the substrate.
Renal cytochroine P450-dependent oxidations.
Although the hepatic cytochrome P-450 system is
well characterized, less is known concerning the
renal cytochrome P-450 system. It has been known
for some time, however, that mixed-function oxi-
dase activities are present in renal tissue [24, 25].
More recently, Ellin et al [26, 27] described the w
and w- 1 hydroxylation of lauric acid in rat kidney
638 Anders
NADPH-cytochrome P-450
reductase
Cyt-Fe2 CO CytFe2
S CO hi' S
Cyt- *2
S °2
e- (NADPH-cytochrome P-450
Cyt—Fe3 Cyt—Fe'2 1 '' reductase or
I I — I I cytochrome b5-NADH-S 02 S °2 j cytochrome b5 reductase
Fig. 1. Electron transfer system for the cytochrome P-450-depende'at oxidation of drugs and chemicals. Cyt = cytochrome P-450, S =
substrate, SOH = oxidized substrate.
cortex microsomes. The renal enzyme system was
similar to that found in the liver in that carbon mon-
oxide inhibited the reaction and that laurate pro-
duced a type I spectral change with oxidized micro-
somal preparations; in contrast, the absorption
maximum of the reduced hemoprotein-carbon-mon-
oxide complex was at 453 to 454 m rather than 450
mt. In addition, evidence was presented suggesting
that the o and o.-i hydroxylation of lauric acid by
liver microsomes was catalyzed by different en-
zymes whereas a single enzyme appeared to be in-
volved in renal fatty acid hydroxylation [28, 29].
Subsequent work has shown that the renal cyto-
chrome P-450 oxidase system catalyzes the metabo-
lism of a variety of chemicals; this information is
summarized in Table 1. With the exception of fatty
acid hydroxylation, renal mixed-function oxidase
activities tend to be much lower than those found in
Table 1. Renal mixed function oxidase activities
Substrate Species Activity, % of liver Ref.
Fatty acids (caprylic,
capric, lauric,
myristic, palmitic) Rat
Rabbit, cortex
Rabbit, outer medulla
Rabbit, inner medulla
426 (lauric, w hydroxylation)
100 (lauric, se-i hydroxylation)
242 (lauric, wand se-i hydroxylation)
35 (laurie, wand se-i hydroxylation)
90 (laurie, wand w-l hydroxylation)
[26—29]
[34]
[34]
[34]
3-Methyl-4-aminoazobenzene Rat 3 [24]
Aminopyrine Human
Rat
Rabbit
Mouse
Hamster
Guineapig
Rabbit, cortex
Rabbit, outer medulla
Rabbit, inner medulla
4
6
<1
5
4
3
31
ND
ND
[30]
[31]
[31]
[31]
[31]
[31]
[34]
[34]
[34]
Biphenyl Rat <7 [31]
Aniline Rat <13 [31]
Dichloromethane Rat 5 [32]
Benzo(a)pyrene Rat 37 [35]
7-Ethoxycoumarin Rat 88 [35]
N-Methyl-p-chloroaniline Rat 51 [33]
Ethylmorphine Rabbit 3 [33]
ND denotes not detected.
S
Cyt-Fe CytFe3
Cyt-Fe4
S 0—
H20
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the liver. Although the renal metabolic rates are
low, activity is present in a variety of species, in-
cluding man.
The renal content of components of the cyto-
chrome P-450-dependent mixed-function oxidase
system have been measured (Table 2). In most spe-
cies studied, the renal cytochrome P-450 and b5
contents are small compared with liver. Extra-
hepatic cytochrome P-450, including kidney, ap-
pears, however, to be immunologically similar to
that of liver [35]. Renal NADPH-cytochrome c re-
ductase activity varies widely among the several
species studied. The low drug metabolic capabilities
of the kidney appear to reflect the low content of
cytochrome P-450.
The distribution of both components and activi-
ties of the mixed-function oxidase system have
been studied in the rabbit kidney (Tables 1 and 2)
[34]. The highest level of cytochrome P-450 was
present in kidney cortex and was not detectable in
either inner or outer medulla; similarly, renal mon-
oxygenase activities were highest in kidney cortex.
The effect of various factors known to alter he-
patic monooxygenase activity have been studied in
extrahepatic tissues, including the kidney [33]. The
sex differences in drug metabolism seen in the rat,
which are marked in the liver, are not observed in
the kidney. Starvation was found to increase both
renal cytochrome P-450 levels and biphenyl-4-hy-
droxylase activity, whereas corresponding values
decreased in the liver. Carbon tetrachioride treat-
ment, which produced dramatic changes in hepatic
drug metabolism, failed to alter several parameters
of renal drug metabolism. Finally, SKF 525-A
(2-diethylaminoethyl 2 ,2-diphenylvalerate hydro-
chloride), a known inhibitor of monooxygenase ac-
tivity [37], inhibited aminopyrine and biphenyl me-
tabolism in both liver and kidney microsomes, but
failed to inhibit ethylmorphine demethylation in the
kidney microsomes.
The in vivo administration of a large number of
compounds is well known to increase hepatic
monooxygenase activity [13]; this response is
termed "enzyme induction." More than 200 com-
pounds have been shown to be inducers of hepatic
mixed function oxidase activity. Two groups of
compounds widely used in induction experiments
are barbiturates, such as phenobarbital, and polycy-
clic hydrocarbons, such as benzo(a)pyrene and 3-
methyicholanthrene. The differences in the effects
of these inducers have been summarized by Parke
[38]. Barbiturate inducers produce marked hepatic
hypertrophy, an increase in both cytochrome P-450
and NADPH-cytochrome P-450 reductase, in-
creased protein and phospholipid synthesis, in-
creased substrate binding (both type I and II), and
increased metabolic activity (for example, ethyl-
morphine N-demethylation, biphenyl 4-hydroxy-
lation). Polycyclic inducers produce little hyper-
trophy, cytochrome P-450 is replaced by cyto-
chrome P-448, NADPH-cytochrome P-450 reduc-
tase is unchanged, a delayed increase in protein
synthesis and little change in phospholipid syn-
thesis, increased substrate binding (type II only),
and increased polycyclic hydrocarbon metabolism
(benzo(a)pyrene hydroxylation).
The mechanisms by which chemicals produce en-
zyme induction have been thoroughly studied [39,
40]. The induction of monooxygenase activity re-
quires chromatin activation and both RNA and pro-
tein synthesis because actinomycin D as well as pu-
romycin and cycloheximide block induction. A re-
ceptor protein has been found in hepatic cytosol
that binds polycyclic hydrocarbons and 2,3,7,8-tet-
Table 2. Renal content of components of the microsomal mixed-function oxidase systems
Species Cytochrome P-450 Cytochrome b5
NADPH-cytochrome c reductase
nmoles cytochrome c reduced/mm/mg ofprotein Ref.
Rat 0072b (14) 0•317b (22) 25.1 (68) [36]
Rat 0.013(l3) — 52.0 (28) [31]
Rabbit 0.023(l3) — 34.0 (22) [31]
Mouse 0.036e (33) — 77.0 (71) [31]
Hamster 0.018c(13) — 62.0 (22) [31]
Guinea Pig 0.029c (23) — 57.0 (25) [31]
Human Trace 009b (19) 10.9 (15) [30]
Rabbit, cortex 0.07" (5) — 12.8 (14) [34]
Rabbit, outer medulla ND — 9.6 (11) [34]
Rabbit, inner medulla ND — 6.4 (7) [34]
a Numbers in parentheses are renal values expressed as a percent of liver values. ND denotes not detected.
Unit of measure is nmoles cytochrome/mg of protein.
Unit of measure is A450_490/mg of protein per ml.
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rachlorodibenzo-p-dioxin (TCDD) and is thought to
trigger the induction process by passing into the nu-
cleus. This protein does not bind barbiturate-type
inducers [41].
Although most induction studies have been car-
ried out using liver tissue, the induction of renal
mixed-function oxidase activity has been investi-
gated. In general, barbiturate-type inducers (pheno-
barbital, PCB) produce little change in renal drug
metabolism, whereas polycyclic hydrocarbon-type
inducers (3-methylcholanthrene, TCDD) produce
dramatic changes. This information is summarized
in Table 3. Important species differences are ob-
served; for example, TCDD is a potent inducer of
renal biphenyl-4-hydroxylase activity in the rat but
not in the mouse or rabbit. Factors affecting extra-
hepatic enzyme induction have been discussed by
Bridges and Fry [47].
The toxicologic consequences of the induction of
renal drug metabolism have been discussed by
Hook and Kiuwe [48].
Oxidation of alcohols and aldehydes. The oxida-
tion of alcohols to aldehydes or ketones and of aide-
hydes to carboxylic acids is a rather common reac-
tion and one of substantial pharmacologic and tox-
icologic importance. Two groups of enzymes
appear to be involved in these oxidative reactions,
namely, pyridine nucleotide-linked oxidases and al-
dehyde oxidase.
The pyridine nucleotide-linked oxido-reductases
are characterized by a preference for NAD over
NADP as a substrate and by subceiiular local-
ization in both the cytosol and mitochondria. They
are also widely distributed in the body. Deitrich [49]
has studied the organ distribution of aldehyde-oxi-
dizing enzymes using indole-3-acetaldehyde as the
substrate. The whole renal homogenate activity was
14 to 18% of that observed in the liver, and female
rats showed twofold higher rates of renal activity.
Eighty percent of the activity present in whole renal
homogenates was due to a cytosolic enzyme, and
the balance was present in mitochondria; these ac-
tivities are attributable to different enzymes. Activi-
ty with NADP was 28% of that observed in the
presence of NAD. Domeyer [50] obtained similar
results using butraldehyde as the substrate. BUttner
[51] compared the alcohol and aidehyde oxidizing
capacity of rat liver and kidney using ethanol and
acetaldehyde as the substrates. Renal alcohol and
aldehyde dehydrogenase activities were about 15
and 20%, respectively, of that seen in the liver in
both male and female rats.
Aidehyde oxidase is a metalloflavoprotein con-
taining iron, molybdenum, and FAD, which can uti-
lize a variety of electron acceptors. Renal aldehyde
oxidase activity, using benzaidehyde as the sub-
strate, was 40% of that observed in the liver [50]; it
should be added, however, that renal aldehyde oxi-
dase activity was less than 10% of renal NAD-
linked dehydrogenase activity, suggesting that this
enzyme is of minor importance.
The effect of structure on the oxidation of aro-
matic aldehydes has been studied in liver and kid-
ney [52]. It was observed that whereas phthalalde-
hydic acid was not oxidized in the kidney, both
isophthaialdehydic acid and terephthaialdehydic
acid were readily oxidized; similar results were
found in both the kidney and liver. Thus, structure
Table 3. Induction of renal mixed-function oxidase activity
Inducer Substrate Species Induced/control Ref.
Phenobarbital Benzo(a)pyrene Mouse
Rat
0.9
1.2
[42]
[43]
3-Methyicholanthrene Benzo(a)pyrene Mouse
Rat
2.9
200.0
[41]
[43]
TCDD Benzo(a)pyrene Mouse
Rat
55.6
60.4
[42]
[45, 46]
PCB' Benzo(a)pyrene Mouse 2.1 [42]
Phenobarbital Bipheny1 Rabbit
Rat
Mouse
2.0
1.0
1.0
[33]
[43]
[42]
Phenobarbital N-Methyl-p-chloroaniline Rabbit
Rat
Mouse
2.1
1.0
1.1
[33]
[43]
[42]
TCDDa Biphenyle Mouse
Rat
Rabbit
2.0
46.0
1.9
[42]
[44]
[44]
a 2,3
,7,8-Tetrachlorodibenzo-p-dioxin
Polychiorinated biphenyls (Arochior 1254)
4-Hydroxylation
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exerts dramatic effects on the renal oxidation of
aromatic aldehydes.
Reductive reactions
Cytochrome P-450-dependent reductions. Hepat-
ic microsomal enzymes are well known to reduce
both azo and nitro compounds [53]. Azoreductase
activity is attributable to both NADPH-cytochrome
c reductase and cytochrome P-450 [54] whereas ni-
troreductase activity is catalyzed by cytochrome P-
450 only [55]. Both p-nitrobenzoate and Prontosil®
are reduced by renal tissue, but at low rates when
compared with liver [53]. In addition, tertiary amine
N-oxides [56] and benzo(a)pyrene 4,5-oxide [57] are
reduced at slow rates by renal cytochrome P-450-
dependent reductases.
Reduction of aldehydes and ketones. Enzymes
catalyzing the reduction of both aldehydes and ke-
tones are widely distributed in the body [58]. These
cytoplasmic enzymes show broad substrate speci-
ficities, and NADPH is utilized as a cofactor [59.-
61]. Significant aldehyde reductase activity, some-
times exceeding that found in liver, was found in
renal tissues of all species studied [61]. For ex-
ample, the rate of the NADPH-dependent reduction
of 3-pyridine-carboxaldehyde by rat kidney is al-
most twice that seen in liver.
Glutathione-dependent reactions. Relatively few
examples of glutathione-dependent reductive reac-
tions are known. Brundin and Anders [62] showed,
for example, that 2,2' ,4'-trichloroacetophenone is
reduced to 2',4'-dichloroacetophenone by gluta-
thione-dependent cytosolic enzymes; activity in
kidney cytosol was 127% of that found in liver cyto-
sol.
Hydrolytic reactions
Esterases. Esterases are ubiquitous in mamma-
lian organisms. These enzymes are important in
many physiologic reactions and are widely distrib-
uted in the body, including the kidney. La Du and
Snady [63] have reviewed the distribution and prop-
erties of human tissue esterases.
Epoxide hydrase. Microsomal epoxide hydrase
catalyzes the conversion of both aliphatic and aro-
matic epoxides to trans-dihydrodiols [64]. Epoxides
are reactive electrophiles, which may interact with
tissue macromolecules and may be involved in the
production of mutagenic and carcinogenic effects
by chemicals. In many cases, epoxide hydrase
serves to detoxify epoxides via conversion to trans-
dihydrodiols. This enzyme, however, may also be
involved in the bioactivation of polycyclic hydro-
carbons because diol epoxides, formed by epoxide
hydrase, are thought to be ultimate carcinogens.
Epoxide hydrase is widely distributed in mam-
malian organs, including the kidney [65]. For
example, renal epoxide hydrase activity, using
benzo(a)pyrene 4,5-oxide or styrene oxide as the
substrate, was about 10% of that observed in the
liver in both rat and mouse; renal epoxide hy-
drase activity was unaltered by treatment with poly-
chlorinated biphenyls (Arochior 1254®). Later stud-
ies showed that trans-stilbene oxide was an ef-
fective inducer of renal epoxide hydrase activity in
the rat, but not in the mouse or hamster [66, 67];
exposure to styrene, cigarette smoke, or 2,3,7,8-tet-
rachlorodibenzo-p -dioxin failed to alter renal ep-
oxide hydrase activity [45, 68-70].
Conjugation reactions
Glucuronide synthesis. Glucuronide conjugates
or /3-D-glucosiduronic acids are formed by combina-
tion of an aglycone with C-i of glucuronic acid (Fig.
2). This reaction is catalyzed by uridine diphosphate
(UDP) glucuronyl transferase, which is located in the
endoplasmic reticulum [71, 72]. Four types of agly-
cones are commonly involved: hydroxyl (both
phenolic and alcoholic), carboxyl, sulfhydryl, and
amino. Because of this diversity, a very large num-
ber of synthetic and biosynthetic glucuronides have
been identified [73]. Glucoronides are very polar
and are readily excreted in the bile or urine. Further-
more, glucuronides, in most cases, possess little or
no biologic activity. Thus, glucuronide formation is
a classic example of a detoxication pathway.
UDP glucuronyl tranferase is found in many tis-
sues of the body, including the kidney; this informa-
tion is summarized in Table 4. It can be seen that
UDP glucuronyl transferase activities vary widely
depending on the species studied and the substrate
used. Overall, it is apparent that the kidney is very
active in forming glucuronides.
Many of the chemicals known to be inducers of
hepatic and renal mixed-function oxidase activity
also stimulate hepatic and renal glucuronyl transfer-
ase activity. These data are presented in Table 5.
Both phenobarbital and 3-methylcholanthrene in-
duce hepatic, but not renal, glucuronyl transferase
activity [78]. In contrast, cinchophen induces glu-
curonyl transferase activity in both the liver and
kidney [79], whereas salicylic acid produces an in-
crease in the kidney but not in the liver [78]. Studies
by Quebbemann and Anders [82] demonstrated the
in vivo renal formation of glucuronide conjugates of
phenol and p-nitrophenol in the chicken. It was also
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observed that administration of salicylic acid to
chickens increased the maximum capacity of the
kidney to transport catechol glucuronide across the
renal tubular cell by 280% [83]. The mechanism by
which salicylic acid increases renal glucu]ronide for-
mation is not understood; this effect, however, may
be of clinical significance in view of the widespread
use of acetylsalicylic acid.
Finally, the recent report by Jones et al. [84]
shows the usefulness of isolated kidney cells for
studying renal drug metabolism. Isolated rat kidney
Table 4. Renal glucuronyl transferase activities
Substrate Species Activity, %ofliver Ref.
4-Methylumbelliferone Rat 32 [73]
p-Nitrophenol Rat
Rabbit
Mouse
Hamster
Guinea pig
75
44
32
36
37
[31]
[31]
[31]
[31]
[31]
o-Aminophenol Rat
Rabbit
Mouse
Hamster
Guinea pig
Chicken
89
<4
70
112
44
22
[31]
[31]
[31]
[31]
[31]
[74]
p-Nitrothiophenol Mouse 120 [75]
Benzoic acid Rat 8 [76]
cells synthesized the glucuronide conjugate of
acetaminophen, and cells isolated from rats given 3-
methyicholanthrene showed an increased rate
(149%) of acetaminophen glucuronide formation.
Rates of glucuronide formation were, however, on-
ly about 5% of that observed in isolated liver cells.
Overall, glucuronide formation is an important
pathway of drug metabolism and one in which the
kidney actively participates.
Sulfate ester synthesis. Sulfate conjugates are
half-esters of sulfuric acid and acceptor compounds
bearing alcoholic or phenolic hydroxyl groups; that
is R-O-SO3H. The acceptor may also be an amine,
in which case sulfamate conjugates (R-NH-SO3H)
are formed. This reaction is catalyzed by sulfotrans-
ferase, a soluble enzyme, which transfers a sulfate
group from 3 '-phosphoadenosine-5 '-phosphosulfate
(PAPS) to alcoholic, phenolic, or amine acceptors
to yield the sulfate ester or sulfamate and 3'-
phosphoadenosine-5'-phosphate (PAP):
R-O-H + PAPS - R-O-SOH + PAP
A large number of sulfate conjugates have been
identified, and these compounds, like glucuronide
conjugates, are very polar and readily excreted in
the urine or bile. Sulfate conjugates, however, have
been shown to be involved in the bioactivation of
Table 5. Induction of renal glucuronyl transferase activity
Inducer Substrate Species Inducedlcontrol Ref.
Salicylic acid o-Aminophenol Rat 1.8 [77]
Phenobarbital o-Aminophenol Rat 1.0 [77]
Cinchophen o-Aminophenol Rat 3.2 to 4.6 [77]
Cinchophen 4-Methylumbelliferone Rat 1.4 [78]
3-Methyicholanthrene p-Nitrophenol Rat 1.6 [79]
3-Methyicholanthrene o-Aminophenol Rat 1.0 [77]
TCDD 4-Methylumbelliferone Rat 1.4 [45]
TCDD p-Nitrophenol Rat 5.4 [44]
Hexabromobiphenyl 4-Methyluinbelliferone Mouse 1.5 [80]
2,3,7,8-Tetrachlorodibenzo-p-dioxin
0- 0-
0— P—O--P—O-CII IIO 0
HO OH
UDP glucuronic acid Glucuronide UDP
Fig. 2. Enzymwic synthesis of glucuronide conjugates. For the glucuronide, R' = RO-, RCOO-, RS- and RNH- in the case of ROH,
RCOOH, RSH and RNH2, respectively.
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Fig. 3. Enzymatic synthesis of glutathione conjugates and rnercapturic acids. R - X = Substrate, A = glutathione (GSH), B = Gluta- 
thione conjugate, C = S-substituted cysteinylglycine, D = S-substituted cysteine, E = rnercapturic acid. 
some compounds [2]. In general, the available pool 
of sulfate is rather limited and rapidly depleted. For 
this reason, sulfate conjugation is often quan- 
titatively less than glucuronide conjugation. The lit- 
erature describing the biosynthesis of sulfate con- 
jugates has been summarized by Roy [85] and De 
Meio [86]. 
Relatively little is known about renal sulfate con- 
jugation. Quebbemann and Anders [82] observed 
the renal formation of phenol andp-nitrophenol sul- 
fate in the intact chicken, Fetal, but not adult, hu- 
man kidney tissue has been shown to catalyze the 
formation of sulfate conjugates of several steroids 
at rates comparable with that observed in liver tis- 
sue [87]. Jones et a1 [84] observed the formation of 
acetaminophen sulfate in isolated rat kidney cells, 
but the rate of sulfate formation was only about 5% 
of that seen in the liver; treatment of rats with 3- 
methylcholanthrene failed to alter renal sulfate for- 
mation. The rate of formation of Cmethylumbel- 
liferone sulfate in rat renal tubule fragments was 
17% of that found in isolated hepatocytes [77]. 
Glutathione conjugates and mercapturic acid 
synthesis. Glutathione conjugates are thioethers 
formed by nucleophilic attack of glutathione on 
electrophilic carbon atoms (Fig. 3) [88]. A wide 
variety of compounds, including alkyl and aryl 
halides, epoxides, and alkenes, have been shown 
to form glutathione conjugates [89, 901. In general, 
the formation of glutathione conjugates serves to 
detoxify reactive electrophilic compounds because 
the resulting conjugates are highly polar and are 
eliminated in the bile or, after conversion to mer- 
capturic acids (S-substituted N-acetylcysteine de- 
rivatives), in the urine. Some glutathione conjuga- 
tion reactions, however, may yield potentially 
toxic products [9l,  921. 
The formation of glutathione conjugates is cata- 
lyzed by glutathione transferase, a soluble enzyme. 
Purification studies show that a family of gluta- 
thione transferases is present in the liver and that 
this group possesses broad and overlapping sub- 
strate specificities [93]. Similarly, several gluta- 
thione transferases have been identified in renal tis- 
sue, but the renal enzymes differ in several ways 
(isoelectric point, substrate specificity, hormonal 
influences, and so forth) from those present in liver 
[94, 951. 
Anders 
Several compounds known to induce hepatic 
monooxygenase activity have been examined for 
their effects on renal glutathione transferase activity 
[96]; phenobarbital and 3,4-benzo(a)pyrene failed to 
alter renal glutathione transferase activity, but 3- 
methylcholanthrene produced a significant increase 
in the glutathione conjugation of several substrates. 
Van Cantfort et a1 [97] observed no increase in renal 
glutathione transferase activity, with benzo(a)- 
pyrene 4,5-oxide as the substrate, after exposure 
to cigarette smoke, phenobarbital, l6a-cyano- 
pregnenolone, or 3-methylcholanthrene. Overall, 
the glutathione transferases are much less respon- 
sive to the effects of inducing agents than are hepatic 
cytochrome P-450-dependent mixed-function oxi- 
dases. 
Although renal glutathione transferase activity is 
much lower than that observed in the liver [96, 971, 
renal metabolism plays a major role in the con- 
version of glutathione conjugates to mercapturic 
acids (Fig. 3). The second step in the formation of 
mercapturic acids is the conversion of glutathione 
conjugates to S-y-glutamylcysteine derivatives. 
This reaction is catalyzed by y-glutamyltranspepti- 
dase, whose activity is highest in the kidney [98]. 
The S_y-glutamylcysteine intermediate is convert- 
ed, by action of a renal peptidase, to a S-substituted 
cysteine conjugate. Finally, the S-cysteine con- 
jugate is acetylated by a microsomal N-acetyl- 
transferase, whose activity is also highest in the kid- 
ney, to yield the mercapturic acid [98, 991. These 
enzyme activities are localized in the outer stripe 
region of the renal medulla (inner cortex), which 
suggests that they are contained in the proximal 
straight tubules [98]. Indeed, S-substituted gluta- 
thione derivatives are very rapidly (tl/z -- 3.5 sec) 
degraded, as shown by microperfusion studies of 
single proximal rat kidney tubules [loo]. 
Renal contribution t o  drug  metabol ism in v ivo 
It is clear that the kidney possesses considerable 
drug-metabolizing capability depending on the sub- 
strate and enzyme involved. Although it is known 
that sulfate and glucuronide conjugates, for ex- 
ample, are formed by the kidney in vivo [82], quan- 
titative estimates of the contribution of renal metab- 
olism to the overall metabolism of drugs and chem- 
icals are generally lacking. 
Diamond and Quebbemann [loll  have recently 
approached this important problem using a variant 
of the isotope dilution method. This method allows 
quantification of the fraction of a metabolite appear- 
ing in the urine that was synthesized by the kidney. 
Using this approach, they studied the renal syn- 
thesis of p-nitrophenol glucuronide and sulfate con- 
jugates in rats given p-nitrophenol. It was observed 
that about 25% and 22% of the endogenously 
formed glucuronide and sulfate conjugates, respec- 
tively, was synthesized and excreted directly by the 
kidney. These are minimum estimates of the contri- 
bution of renal metabolism, because they do not ac- 
count for conjugates synthesized by the kidney that 
were absorbed into the general circulation. Thus, it 
is apparent that the kidneys may make substantial 
contributions to the metabolism of drugs and chem- 
icals. 
Summary. Recent studies show that the kidney 
metabolizes a variety of drugs and chemicals. Renal 
enzymes catalyze oxidative, reductive, hydrolytic, 
and synthetic or  conjugative reactions. The most 
important oxidative reactions are catalyzed by the 
cytochrome P-450-dependent mixed-function oxi- 
dase system; these consist of aromatic and aliphatic 
hydroxylations, N-, 0- and S-dealkylations, and ep- 
oxidation. Reductive reactions, such as the con- 
version of aldehydes and ketones to alcohols, are 
well known to occur in renal tissue. The hydrolysis 
of esters and amides is also catalyzed by renal en- 
zymes, and epoxide hydrase activity is present in 
the kidney. A variety of conjugates, such as glu- 
curonides, sulfate esters, and glutathione con- 
jugates, are formed by renal enzymes. Recent stud- 
ies, in which the contribution of renal metabolism to 
the total conjugative metabolism of phenols has 
been quantified, show that the kidney makes a sig- 
nificant contribution to total metabolite production. 
Reprint requests to Prof. M .  W .  Anders, Department of Phar- 
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